title: Hemophagocytic syndrome in ileum-origin B-cell lymphoma.
abstract: A 56 year-old-man was admitted due to upper abdominal tumor and was diagnosed as having stage IVb diffuse B-cell malignant lymphoma that originally developed in the terminal ileum. The first and the second administrations of CHOP (cyclophosphamide, 750 mg/m(2); adriamycin, 50 mg/m(2); vincristine, 1.4 mg/m(2); and prednisolone, 100 mg/day) therapy were effective; however, the third course of therapy was postponed because of an episode of massive hematochezia. After this episode, lymph nodes began to enlarge and progressive pancytopenia occurred. Bone marrow smear showed the proliferation of reactive histiocytic cells which phagocytized red blood cells, white blood cells, and platelets. B-cell lymphoma-associated hemophagocytic syndrome (B-LAHS) was diagnosed. This case is extremely rare because: (1) LAHS occurred in an ileum-origin B-cell lymphoma, and (2) LAHS developed during an interval after chemotherapy.
authors: Digestive and Liver Disease Center, Tokai University Tokyo Hospital, 1-2-5 Yoyogi, Shibuya-ku, 153-0065, Tokyo, Japan.
authors: Shigeyuki
authors: S
authors: Motegi
authors: Yasuhiro
authors: Y
authors: Nishizaki
authors: Chikashi
authors: C
authors: Muramatsu
authors: Hiroyuki
authors: H
authors: Nakamura
authors: Fuminori
authors: F
authors: Kobayashi
authors: Hirokazu
authors: H
authors: Shiozawa
authors: Junichiro
authors: J
authors: Kamochi
authors: Masaru
authors: M
authors: Itakura
authors: Makoto
authors: M
authors: Shibuya
authors: Tetsuhei
authors: T
authors: Ogawa
authors: Shohei
authors: S
authors: Matsuzaki
mesh_terms: D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003113:Colonoscopy; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use; D004317:Doxorubicin / Q000008:administration & dosage / Q000627:therapeutic use; D020031:Epstein-Barr Virus Infections / Q000175:diagnosis / Q000821:virology; D004854:Herpesvirus 4, Human; D015616:Histiocytosis, Non-Langerhans-Cell / Q000175:diagnosis* / Q000821:virology; D006801:Humans; D007078:Ileal Neoplasms / Q000175:diagnosis* / Q000188:drug therapy; D016393:Lymphoma, B-Cell / Q000175:diagnosis* / Q000188:drug therapy; D016403:Lymphoma, Large B-Cell, Diffuse / Q000175:diagnosis* / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D011239:Prednisolone / Q000008:administration & dosage; D011241:Prednisone / Q000627:therapeutic use; D014057:Tomography, X-Ray Computed; D017211:Treatment Failure; D014750:Vincristine / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D000903:Antibiotics, Antineoplastic; D000970:Antineoplastic Agents; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone; D011241:Prednisone